Author Correction: Scribble mis-localization induces adaptive resistance to KRAS G12C inhibitors through feedback activation of MAPK signaling mediated by YAP-induced MRAS

• by Yuta Adachi, Ryo Kimura, Kentaro Hirade, Shogo Yanase, Yuki Nishioka, Natsumi Kasuga, Rui Yamaguchi, Hiromichi Ebi

• October 19, 2026

Influence of virtual dynamic contrast enhanced breast MRI on lesion size, BI-RADS scores and reader confidence

• by Andrzej Liebert, Hannes Schreiter, Lorenz A. Kapsner, Jessica Eberle, Chris M. Ehring, Dominique Hadler, Sabine Ohlmeyer, Frederik B. Laun, Ramona Erber, Julius Emons, Michael Uder, Evelyn Wenkel, Sebastian Bickelhaupt

• October 17, 2026

Immune and cellular determinants of response to HMA-venetoclax regimens in acute myeloid leukemia

• by Alfredo Marchetti, Francesca Lazzaroni, Matteo Claudio Da Via', Marta Lionetti, Giulia Maggioni, Alessia Campagna, Denise Ventura, Giorgio A. Croci, Alessio Marella, Akihiro Maeda, Antonio Matera, Emanuele Calvi, Margherita Scopetti, Filippo Viviani, Nicolò Rampi, Davide Bonometti, Elena Benzoni, Manuela Zappa, Sonia Fabris, Marzia Barbieri, Stefania Pioggia, Claudia Leoni, Antony Ricchiuti, Matteo G. D. Porta, Mariarita Sciumè, Francesco Passamonti, Nicola S. Fracchiolla, Niccolò Bolli

• October 13, 2026

2026 ASCO Breast Cancer Highlights: PANKU-Breast02

Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new results from the PANKU-Breast02 Study on a new dual-antibody drug conjugate, called izalontamab brengitecan (iza-bren), for metastatic triple-negative breast cancer.

• October 15, 2026

• 1 min